跳至主要内容
临床试验/NCT05391659
NCT05391659Unknown不适用

E-CLAIR: Efficiency and Cost-effectiveness of Artificial Intelligence Based Diabetic Retinopathy Screening in Flanders

Universitaire Ziekenhuizen KU Leuven4 个研究点 分布在 1 个国家目标入组 1,200 人开始时间: 2021年6月17日最近更新:
适应症

试验速览

阶段
不适用
入组人数
1,200
试验地点
4
主要终点
sensitivity

研究概览

简要总结

To evaluate the efficiency and cost-effectiveness of an artificial intelligence based diabetic retinopathy screening program in Flanders

详细描述

The increase of diabetes patients is a 21st century global health challenge with a predicted 642 million people suffering from the disease by 2040. Diabetes mellitus is characterized by high blood sugar levels over a prolonged period of time. These uncontrolled blood sugar levels can damage the inner lining of blood vessels which on the long term causes microvascular complications that affect small blood vessels. Retinopathy is the most prevalent microvascular complication of diabetes and is caused by small blood vessel damage, and neural damage at the back layer of the eye, the retina.

Diabetic retinopathy (DR) is the leading cause of blindness and visual disability in the working population. According to a study of the Eye Diseases Prevalence Research group, 40% of adult diabetes patients in the United States have some degree of DR and 8% have vision-threatening forms of DR. In addition, the DR Barometer study indicated that many patients with diabetes do not have a regular appointment with ophthalmology for an eye examination. Risk of vision loss can be significantly decreased with annual retinal screening and detection of cases that need to be referred for follow-up and treatment. The best example showing the value of eye screening is from the United Kingdom (UK). As a result of an implementation of a nationwide screening program, DR is no longer the leading cause of irreversible blindness in the UK.

In Flanders, and in Belgium as a whole, no such well-organized, nationwide DR screening program is in place and the approach is more fragmented. Flemish guidelines for diabetes care recommend an annual visit to the ophthalmologist for all the diabetic patients who receive insulin therapy in order to check if they have DR. About 30% of the diabetics will be diagnosed for DR and 70% are disease free or in a very early stage that doesn't need further treatment. However, manual detection of DR performed by an occupied, scarce ophthalmologist is labor-intensive and expensive, causing long waiting times for the patient and possibly resulting in a lack of care when needed.

Given the extent of the diabetes population in Flanders it is self-evident that there are difficulties to screen all patients in a timely manner by ophthalmologists. Indeed, a large amount of diabetes type 2 patients do not follow the annual referral by their general practitioner (GP) and are therefore screened at a too late stage, resulting in high, avoidable costs for the patient and society. Even more, the screening of the diabetic patients by an ophthalmologist put a resource burden on our healthcare system. Task differentiation, where trained graders or GP's instead of ophthalmologists grade for referable DR, can offer a solution for the too long waiting times and the high cost. Nevertheless, manual grading of DR still is labor-intensive and costly. Even more, despite the implementation of nationwide screening programs for DR and their accompanying grading protocols, there is still substantial room for improvement in the accuracy of manual DR grading.

Recently, deep learning (DL), a form of artificial intelligence (AI), has been introduced for automated analysis of images. In a landmark paper, Gulshan and co-workers published on a deep learning algorithm with high sensitivity and specificity for detecting referable DR. This study paved the way for further developments in the field of deep learning for automated DR detection, resulting in DL models that achieve specialist-level accuracy in diagnosing DR severity. IDx, for example, obtained the first-ever FDA authorization for an AI diagnostic system in any field of medicine for DR detection.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of diabetes mellitus
  • Age > 18 years old
  • Patient is capable of giving informed consent
  • Fluent in written and oral Dutch, or interpreter present

排除标准

  • - History of treatment for diabetic retinopathy or diabetic macular edema (laser or intravitreal injections)
  • Participant is contraindicated for imaging by fundus imaging systems used in the study

结局指标

主要结局

sensitivity

时间窗: 6 months

To evaluate the efficiency of the use of AI in screening for DRP: sensitivity

specificity

时间窗: 6 months

To evaluate the efficiency of the use of AI in screening for DRP: specificity

AUC

时间窗: 6 months

To evaluate the efficiency of the use of AI in screening for DRP: AUC

次要结局

  • precision(6 months)
  • F1 score(6 months)
  • recall(6 months)
  • decision tree model(6 months)
  • false positives and false negatives(6 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

JulieJacob

Ophthalmologist

Universitaire Ziekenhuizen KU Leuven

研究点 (4)

Loading locations...

相似试验